942986-68-7 Usage
Uses
Used in Pharmaceutical Industry:
(2R)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl-acetic acid is used as a key intermediate in the synthesis of various bioactive molecules for pharmaceutical applications. Its unique structure and chirality make it a valuable building block for the development of new drugs with potential therapeutic benefits.
Used in Medicinal Chemistry Research:
(2R)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl-acetic acid is used as a research compound in medicinal chemistry to explore its potential as a lead compound for the development of new pharmaceutical agents. Its quinoxaline ring system and carboxylic acid functionality provide opportunities for further chemical modifications and optimization to enhance its biological activity and pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 942986-68-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,2,9,8 and 6 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 942986-68:
(8*9)+(7*4)+(6*2)+(5*9)+(4*8)+(3*6)+(2*6)+(1*8)=227
227 % 10 = 7
So 942986-68-7 is a valid CAS Registry Number.
942986-68-7Relevant academic research and scientific papers
N-aryl-[(2R)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]acetamide as antifungal agents
Goel, Kapil Kumar,Gupta, Prasoon,Patil, Shailendra,Gajbhiye, Asmita
experimental part, p. 4705 - 4706 (2012/02/16)
A series of N-aryl-2-[(2R)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl] acetamide have been synthesized by the condensation of substituted anilines with 3a,4-dihydrofuro[2,3-b]quinoxalin-2(3H)-one. The structures of the synthesized compounds have been establi
Development of an efficient and selective radioligand for bradykinin B 1 receptor occupancy studies
Su, Dai-Shi,Markowitz, M. Kristine,Murphy, Kathy L.,Wan, Bang-Lin,Zrada, Matthew M.,Harrell, C. Meacham,O'Malley, Stacy S.,Hess, J. Fred,Ransom, Rick W.,Chang, Ray S.,Wallace, Michael A.,Raab, Conrad E.,Dean, Dennis C.,Pettibone, Douglas J.,Freidinger, Roger M.,Bock, Mark G.
, p. 6045 - 6048 (2007/10/03)
We have developed an efficient and selective radioligand, the [ 35S]-radiolabeled dihydroquinoxalinone derivative, 4, for an ex vivo receptor occupancy assay in transgenic rats over-expressing the human bradykinin B1 receptor.
